AI-Based Neoantigen Prediction Model Found Very Accurate

A France-based biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, announced that they will present data demonstrating that the prediction algorithm used to customize the TG4050 vaccine candidate for each patient is accurate at identifying immunogenic cancer mutations.

These data were jointly generated by the Transgene, NEC, and NEC Laboratories Europe GmbH teams and will be presented at the upcoming meeting of the American Association for Cancer Research Annual Meeting 2020.

TG4050 is an individualized therapeutic vaccine based on Transgene’s myvac® technology. 

This cancer vaccine candidate is powered by NEC’s cutting-edge AI capabilities. 

Two Phase 1 trials with TG4050 are ongoing in Europe and in the USA.

TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations) which are selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. 

The prediction system is based on more than 2-decades of expertise in AI and has been trained on proprietary immune data, allowing it to accurately prioritize and select the most immunogenic sequences.

To evaluate the accuracy of the prediction, samples from cancer patients were collected. 

Healthy and tumor tissue were sequenced, and mutations were identified and ranked using the algorithm. 

These were then evaluated by measuring the frequency of T cells against the predicted antigens. 

Although preliminary, the results generated to-date suggests that the system can identify rare immunogenic mutations among a large list of candidates identified in the patients.

Transgene uses its expertise in viral vectorization to incorporate the selected neoantigen sequences in the genome of the Modified Vaccinia virus Ankara viral vector. 

The Company has set up a unique in-house good manufacturing practice unit dedicated to manufacturing the individualized batches of TG4050 needed for the clinical development of this novel individualized therapeutic vaccine.

Transgene is a publicly-traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. 

Cancer vaccine development news published by Vax-Before-Cancer.